Cargando…

Merkel Cell Carcinoma—Update on Diagnosis, Management and Future Perspectives

SIMPLE SUMMARY: Merkel cell carcinoma (MCC) is a highly aggressive skin cancer and the second cause of skin cancer death after melanoma. MCC is an immunogenic tumor. In recent years, the use of immunotherapy has changed the treatment landscape for patients with metastatic MCC, significantly improvin...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaggana, Eleni, Konstantinou, Maria Polina, Krasagakis, Gregor Herrmann, de Bree, Eelco, Kalpakis, Konstantinos, Mavroudis, Dimitrios, Krasagakis, Konstantinos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817518/
https://www.ncbi.nlm.nih.gov/pubmed/36612102
http://dx.doi.org/10.3390/cancers15010103
_version_ 1784864769839202304
author Zaggana, Eleni
Konstantinou, Maria Polina
Krasagakis, Gregor Herrmann
de Bree, Eelco
Kalpakis, Konstantinos
Mavroudis, Dimitrios
Krasagakis, Konstantinos
author_facet Zaggana, Eleni
Konstantinou, Maria Polina
Krasagakis, Gregor Herrmann
de Bree, Eelco
Kalpakis, Konstantinos
Mavroudis, Dimitrios
Krasagakis, Konstantinos
author_sort Zaggana, Eleni
collection PubMed
description SIMPLE SUMMARY: Merkel cell carcinoma (MCC) is a highly aggressive skin cancer and the second cause of skin cancer death after melanoma. MCC is an immunogenic tumor. In recent years, the use of immunotherapy has changed the treatment landscape for patients with metastatic MCC, significantly improving the prognosis. However, the five-year disease-specific survival remains around 64%, underlying the unmet need for novel treatments. This review recapitulates current knowledge about MCC pathogenesis, diagnosis, and management. Emphasis is given to the use of immunotherapy and targeted therapies as well as to future therapeutic perspectives in the neoadjuvant setting and for locally advanced and metastatic MCC. ABSTRACT: MCC is a rare but highly aggressive skin cancer. The identification of the driving role of Merkel cell polyomavirus (MCPyV) and ultraviolet-induced DNA damage in the oncogenesis of MCC allowed a better understanding of its biological behavior. The presence of MCPyV-specific T cells and lymphocytes exhibiting an ‘exhausted’ phenotype in the tumor microenvironment along with the high prevalence of immunosuppression among affected patients are strong indicators of the immunogenic properties of MCC. The use of immunotherapy has revolutionized the management of patients with advanced MCC with anti-PD-1/PD L1 blockade, providing objective responses in as much as 50–70% of cases when used in first-line treatment. However, acquired resistance or contraindication to immune checkpoint inhibitors can be an issue for a non-negligible number of patients and novel therapeutic strategies are warranted. This review will focus on current management guidelines for MCC and future therapeutic perspectives for advanced disease with an emphasis on molecular pathways, targeted therapies, and immune-based strategies. These new therapies alone or in combination with anti-PD-1/PD-L1 inhibitors could enhance immune responses against tumor cells and overcome acquired resistance to immunotherapy.
format Online
Article
Text
id pubmed-9817518
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98175182023-01-07 Merkel Cell Carcinoma—Update on Diagnosis, Management and Future Perspectives Zaggana, Eleni Konstantinou, Maria Polina Krasagakis, Gregor Herrmann de Bree, Eelco Kalpakis, Konstantinos Mavroudis, Dimitrios Krasagakis, Konstantinos Cancers (Basel) Review SIMPLE SUMMARY: Merkel cell carcinoma (MCC) is a highly aggressive skin cancer and the second cause of skin cancer death after melanoma. MCC is an immunogenic tumor. In recent years, the use of immunotherapy has changed the treatment landscape for patients with metastatic MCC, significantly improving the prognosis. However, the five-year disease-specific survival remains around 64%, underlying the unmet need for novel treatments. This review recapitulates current knowledge about MCC pathogenesis, diagnosis, and management. Emphasis is given to the use of immunotherapy and targeted therapies as well as to future therapeutic perspectives in the neoadjuvant setting and for locally advanced and metastatic MCC. ABSTRACT: MCC is a rare but highly aggressive skin cancer. The identification of the driving role of Merkel cell polyomavirus (MCPyV) and ultraviolet-induced DNA damage in the oncogenesis of MCC allowed a better understanding of its biological behavior. The presence of MCPyV-specific T cells and lymphocytes exhibiting an ‘exhausted’ phenotype in the tumor microenvironment along with the high prevalence of immunosuppression among affected patients are strong indicators of the immunogenic properties of MCC. The use of immunotherapy has revolutionized the management of patients with advanced MCC with anti-PD-1/PD L1 blockade, providing objective responses in as much as 50–70% of cases when used in first-line treatment. However, acquired resistance or contraindication to immune checkpoint inhibitors can be an issue for a non-negligible number of patients and novel therapeutic strategies are warranted. This review will focus on current management guidelines for MCC and future therapeutic perspectives for advanced disease with an emphasis on molecular pathways, targeted therapies, and immune-based strategies. These new therapies alone or in combination with anti-PD-1/PD-L1 inhibitors could enhance immune responses against tumor cells and overcome acquired resistance to immunotherapy. MDPI 2022-12-23 /pmc/articles/PMC9817518/ /pubmed/36612102 http://dx.doi.org/10.3390/cancers15010103 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Zaggana, Eleni
Konstantinou, Maria Polina
Krasagakis, Gregor Herrmann
de Bree, Eelco
Kalpakis, Konstantinos
Mavroudis, Dimitrios
Krasagakis, Konstantinos
Merkel Cell Carcinoma—Update on Diagnosis, Management and Future Perspectives
title Merkel Cell Carcinoma—Update on Diagnosis, Management and Future Perspectives
title_full Merkel Cell Carcinoma—Update on Diagnosis, Management and Future Perspectives
title_fullStr Merkel Cell Carcinoma—Update on Diagnosis, Management and Future Perspectives
title_full_unstemmed Merkel Cell Carcinoma—Update on Diagnosis, Management and Future Perspectives
title_short Merkel Cell Carcinoma—Update on Diagnosis, Management and Future Perspectives
title_sort merkel cell carcinoma—update on diagnosis, management and future perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817518/
https://www.ncbi.nlm.nih.gov/pubmed/36612102
http://dx.doi.org/10.3390/cancers15010103
work_keys_str_mv AT zagganaeleni merkelcellcarcinomaupdateondiagnosismanagementandfutureperspectives
AT konstantinoumariapolina merkelcellcarcinomaupdateondiagnosismanagementandfutureperspectives
AT krasagakisgregorherrmann merkelcellcarcinomaupdateondiagnosismanagementandfutureperspectives
AT debreeeelco merkelcellcarcinomaupdateondiagnosismanagementandfutureperspectives
AT kalpakiskonstantinos merkelcellcarcinomaupdateondiagnosismanagementandfutureperspectives
AT mavroudisdimitrios merkelcellcarcinomaupdateondiagnosismanagementandfutureperspectives
AT krasagakiskonstantinos merkelcellcarcinomaupdateondiagnosismanagementandfutureperspectives